Valeant Pharmaceuticals Edges Up Almost 1%

Valeant Pharmaceuticals International is up almost 1% after the company said results were positive from a Phase 3, multicenter double-blind, randomized, vehicle-controlled clinical study assessing the safety and efficacy of IDP-118 lotion in treating plaque psoriasis.

Within the Phase 3 study of 215 adult subjects with moderate to severe psoriasis, IDP-118 showed statistical significance to vehicle with a treatment success rate of 45.33%. The primary endpoint of the 12-week study was achievement of a “clear” to “almost clear” score based on an Investigator Global Assessment (IGA) at 8 weeks, and at least 2 grade improvement in the IGA at weeks 12, 6, 4 and 2 as secondary endpoints, the company said.

Leave a Comment